10 mg · 20 mg · 30 mg · 50 mg
Retatrutide
Investigational peptide targeting GIP, GLP-1 and glucagon receptors. Studied in clinical trials on body weight and glycemic control.
For research use only
Vesugen
Synthetic tripeptide (Lys-Glu-Asp) from the short bioregulator peptide family, studied in vascular endothelium and atherosclerosis research.
- Pay by card (Stripe) or Zelle
- Ships within the U.S. with tracking
- Questions? Call or email us
Benefits under study
Preclinical research in cell and vascular models.
- Vascular endothelial cell proliferation
- Atherosclerosis and restenosis models
- Gene expression during aging
Research overview
Vesugen is a synthetic tripeptide with the sequence Lys-Glu-Asp (KED), one of the short regulatory peptides studied by V. Khavinson's research group for vascular tissue.
Published research has examined its role in vascular endothelial cell proliferation during aging and the molecular aspects of its activity in atherosclerosis and restenosis models.
Supplied as a vial for laboratory research.
Scientific references
Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging
Adv Gerontol, 2014 · PMID 25051766
View on PubMedMolecular aspects of anti-atherosclerotic effects of short peptides
Bull Exp Biol Med, 2014 · PMID 25408528
View on PubMed
You may also need
10 mg · 20 mg
Tesamorelin
GHRH analog studied in GH/IGF-1 signaling and visceral fat, including trials in people with HIV and altered fat distribution.
100 mg
KLOW
Blend of GHK-Cu, BPC-157, TB-500 and KPV. Studies on the individual components do not evaluate the blend.